Previous close | 63.40 |
Open | 63.40 |
Bid | 74.60 |
Ask | 83.00 |
Strike | 915.00 |
Expiry date | 2024-06-21 |
Day's range | 63.40 - 63.40 |
Contract range | N/A |
Volume | |
Open interest | 26 |
We recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we discuss whether Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is the best bet in the gene therapy sector. Gene therapy involves treating illnesses by modifying, replacing, or supplementing faulty or missing genes responsible for a disease. This approach […]
On Friday, the FDA extended the target action date of priority review of supplemental application seeking approval for Dupixent (dupilumab) as an add-on maintenance treatment in certain adult patients with uncontrolled chronic obstructive pulmonary disease (COPD), a lung disease that’s usually caused by smoking. The revised target action date is September 27, 2024. The FDA accepted the application in February, with a target action date of June 27, 2024. The FDA did not raise any concerns regardi
Per the FDA, the data submitted by Sanofi (SNY)/Regeneron (REGN) for Dupixent in COPD indication constitutes a major amendment to its previously-submitted data. A final decision is expected by Sep 27.